<DOC>
	<DOCNO>NCT00426998</DOCNO>
	<brief_summary>The purpose research study compare different timing therapy Verteporfin Bevacizumab treat choroidal neovascularization ( CNV ) due age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Combination Bevacizumab Verteporfin ( Two Different Sequences Treatment ) Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>1 . Patients men woman age 55 old 2 . Patients subfoveal CNV due AMD lesion size le equal 9 MPS DA 3. patient receive previous treatment subfoveal CNV due AMD . 4 . Patients visual acuity 20/40 20/320 1 . Subjects receive previous treatment subfoveal CNV , study eye include prior PDT , transpupillary thermotherapy ( TTT ) , submacular surgery , drug therapy Macugen antiangiogenic compound , local treatment . Previous laser photocoagulation therapy acceptable , provided subfoveal . 2 . Patients know hypersensitivity/allergy verteporfin , porfimer sodium , porphyrin , porphyria porphyrin sensitivity , hypersensitivity sunlight bright artificial light . 3 . Patients use medication may induce photosensitivity . 4 . Patients undergone YAG capsulotomy within last month . 5 . Subjects currently involve experimental procedure within last 12 week . 6 . Female patient pregnant , fecund breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Choroidal neovascularization due age-related macular degeneration</keyword>
</DOC>